ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,107,000 | -7.7% | 6,639 | -14.6% | 0.00% | -25.0% |
| Q3 2020 | $1,199,000 | +7.9% | 7,771 | +3.4% | 0.00% | 0.0% |
| Q2 2020 | $1,111,000 | +71.5% | 7,515 | +30.6% | 0.00% | +33.3% |
| Q1 2020 | $648,000 | -27.8% | 5,754 | -10.8% | 0.00% | 0.0% |
| Q4 2019 | $898,000 | +88.7% | 6,452 | +30.4% | 0.00% | +50.0% |
| Q3 2019 | $476,000 | -9.8% | 4,947 | +8.0% | 0.00% | 0.0% |
| Q2 2019 | $528,000 | +1.1% | 4,582 | +3.3% | 0.00% | 0.0% |
| Q1 2019 | $522,000 | +35.6% | 4,435 | -27.9% | 0.00% | 0.0% |
| Q4 2018 | $385,000 | -21.6% | 6,147 | -11.3% | 0.00% | 0.0% |
| Q3 2018 | $491,000 | +13.4% | 6,933 | +6.6% | 0.00% | 0.0% |
| Q2 2018 | $433,000 | -34.2% | 6,502 | -35.4% | 0.00% | -33.3% |
| Q1 2018 | $658,000 | +139.3% | 10,059 | +46.5% | 0.00% | +200.0% |
| Q4 2017 | $275,000 | +14.1% | 6,868 | +3.1% | 0.00% | 0.0% |
| Q3 2017 | $241,000 | +18.7% | 6,659 | -8.1% | 0.00% | 0.0% |
| Q1 2017 | $203,000 | – | 7,242 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |